ArticleFrontiers in oncology2025
CT-based deep learning for preoperative prediction of pathological grading of renal clear cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To construct a noninvasive preoperative prediction model for WHO/ISUP grading of renal clear cell carcinoma (ccRCC) using deep learning combined with four-phase CT images, and to evaluate its efficacy. Methods: A retrospective study was conducted on 158 ccRCC patients (124 low-grade, 34 high-grade) from the Affiliated Hospital of Hebei University (January 2022-June 2024). Patients were randomly divided into training, validation, and test sets at an 8:1:1 ratio. Four-phase CT images were preprocessed (rectangular box annotation of tumor region of interest [ROI], image resizing to 224×224 pixels). The ResNet34 model was first built to predict ccRCC grading, with performance evaluated by accuracy (ACC) and area under the receiver operating characteristic curve (AUC). The model was then optimized by integrating the SENet attention mechanism (forming the SE-ResNet34 model), and performance before and after optimization was compared. Results: ResNet34 models based on corticomedullary, parenchymal, and excretory phase images achieved ACC >0.8, with the parenchymal phase model showing the best performance (ACC = 0.867, low-grade AUC = 0.857, high-grade AUC = 0.853). After adding the SENet attention mechanism, the SE-ResNet34 model exhibited improved performance: ACC increased to 0.878, low-grade AUC to 0.929, and high-grade AUC to 0.927. Conclusion: The SE-ResNet34 model based on parenchymal phase CT images has excellent ability to differentiate WHO/ISUP grades of ccRCC, providing an effective noninvasive auxiliary tool for preoperative pathological grading prediction in clinical practice. However, the model's robustness and multi-center applicability need further validation before clinical use."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.